Drug Development

Share SHARE

badmedicine-093014.jpg The FDA has warned doctors that there has been an increase in the number of wholesale distributors selling fake drugs on the rise. "While the U.S. health care supply chain is one of the most secure and sophisticated in the world, there is a growing network of rogue wholesale drug distributors selling potentially unsafe drugs in the U.S. market," says the FDA.

FDA-091614.jpg The FDA has issued its approval on a new constipation drug from Nektrar Pharma and AstraZeneca. The new drug, called Movantik (naloxegol), is aimed at reducing the constipation associated with opioid pain killers without reducing the central pain killing effects. It is the first drug in its class approved by the FDA and is likely to hit the market two to three years before any competing drugs.

AlzheimerAssociation-040611.jpg A new study suggests that older adults who regularly use sedatives for anxiety or insomnia may have a heightened risk of developing Alzheimer's disease. The drugs in question are benzodiazepines, sedatives that include lorazepam (Ativan), diazepam (Valium) and alprazolam (Xanax). The study, published online in journal BMJ, examined the histories of nearly 1,800 older adults with Alzheimer's.